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ABSTRACT
Objectives: To review randomized controlled trials (RCTs) evaluating the effects of Chinese herbal medi-
cine for treating severe acute respiratory syndrome (SARS) systematically.
Design: Electronic and manual searches identified RCTs comparing Chinese medicine integrated to con-
ventional medicine versus conventional medicine alone. Methodological quality of trials was assessed by gen-
eration of allocation sequence, allocation concealment, blinding, and intention-to-treat.
Results: Eight RCTs (488 patients with SARS) were included. The methodological quality was generally
low. The combined therapy showed significant reduction of mortality (relative risk 0.32 [95% confidence in-
terval {CI} 0.12 to 0.91]), shortened duration of fever, symptom relief, reductions in chest radiograph abnor-
malities, and reductions in secondary fungal infections among patients receiving glucocorticoids. There were
no significant effects on quality of life or glucocorticoid dosage.
Conclusion: Chinese herbal medicine combined with conventional medicine may have beneficial effects in
patients with SARS. The evidence is insufficient because of the low methodological quality of the included tri-
als.
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INTRODUCTION
Severe acute respiratory syndrome (SARS) emerged inNovember 2002 as a highly infectious disease associated
with substantial morbidity and mortality. SARS caused 916
deaths before temporarily disappearing in the summer of
2003. Three new cases of laboratory-confirmed infection
emerged in January 2004 (www.who.int/csr/don/2004_
01_31/en/). The World Health Organization (WHO) esti-
mates that the case fatality rate varies depending on age
group: the rate is less than 1% in persons aged 24 years or
younger; 6% in persons aged 25 to 44 years; 15% in per-
sons aged 45 to 64 years; and greater than 50% in persons
aged 65 years and older (Donnelly et al., 2003; World Health
Organization, 2003b).
Caused by a novel coronavirus, SARS is predominantly
spread by infected water droplets across short distance
among close contacts, although indirect transmission is also
possible (Mora et al., 2003; Peiris et al., 2003; Rota et al.,
2003). Medical personnel are among those commonly in-
fected because of their close contact with symptomatic and
highly infectious cases. The advent of SARS poses an im-
mense challenge to the affected health care communities and
economies.
There is no consensus on the preferred treatment for
SARS. Treatments used to date have been based on patho-
physiologic rationale or on the experience obtained from
case series collected during the early stages of the epidemic.
Glucocorticoids and ribavirin have been administered most
frequently during the early stages of the epidemic, yet in-
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sufficient evidence exists for their efficacy (Wenzel and Ed-
mond, 2003; Wong and Hui, 2003). Antibiotics, other an-
tiviral drugs (e.g., interferon, neuraminidase inhibitor), and
other supportive treatments have also been widely used.
Based on the anecdotal experience of traditional Chinese
doctors in Guangzhou, different herbal medicines were com-
bined with the conventional drugs, and this combined ap-
proach was claimed to be more effective than conventional
drugs alone (Anonymous, 2003; Lin et al., 2003; Ma, 2003).
In April 2003, China’s State Administration of Tradi-
tional Chinese Medicine (TCM; 2003) and the Chinese Min-
istry of Health coannounced an advocacy for the use of
herbal medicines in the treatment of SARS. Eight specific
herbal formulations were recommended after a screening of
more than 30 herbal medicines used for SARS patients
(Duan, 2003; Wang, 2003). The eight formulae are Ban-
langen Keli (Baphicacanthi granule), Jinlian Qingre gran-
ule, Xinxue granule, and Dengzhan Xixin, Fufang Kushen,
Qingkailing, Xiangdan, and Yuxingcao injections. More than
half of patients with SARS in Beijing received treatment
with herbal medicine plus conventional drugs, according to
the State Administration of TCM (Duan, 2003).
Clinical studies, ranging from case reports and case se-
ries to controlled observational studies and randomized clin-
ical trials, have been conducted and reported. Clearly, there
is a critical need to investigate systematically the beneficial
and harmful effects of TCM approaches for treating SARS.
MATERIALS AND METHODS
Search strategy
To identify relevant studies, we searched the following
databases from November 2002 through December 2003:
The Cochrane Library, PubMed, Chinese Biomedical Data-
base, Chinese Journals Full-text Database, Chinese Scien-
tific Journal Database, trials database of the Cochrane Col-
laboration Complementary Medicine Field, and the Allied
and Complementary Database. We used the search terms
“atypical pneumonia,” “severe acute respiratory syndrome,”
“SARS,” “Traditional Chinese Medicine,” “herbal medi-
cine,” and “integrative medicine.” Various combinations of
the terms were used, depending on the database searched.
Relevant Chinese newspapers and Internet websites such as
WHO, U.S. Centers for Disease Control (CDC), and China
CDC were also screened, and reference lists of identified
papers and review articles were checked.
Inclusion criteria
We included randomized clinical trials comparing herbal
medicines plus conventional drugs versus placebo/no inter-
vention plus conventional drugs in patients with SARS on
clinical outcomes. In an exploratory analysis, we included
nonrandomized controlled studies on medicinal herbs com-
pared to placebo/no intervention to investigate the potential
impact of study design on the primary outcome measure
(death). Eligible studies had to include patients meeting the
WHO criteria for a confirmed or suspected case of SARS
(www.who.int/csr/sars/) (during the earliest stage of the
SARS epidemic, patients with SARS were diagnosed as
“atypical pneumonia” in China, and the diagnostic criteria
of “atypical pneumonia” conformed to the WHO criteria).
Published and unpublished studies were included irrespec-
tive of languages or masking. When more than one publi-
cation described a single study, we extracted data from the
one providing the most detailed information.
Validity assessment
The methodological quality of trials was assessed using
the generation of the allocation sequence, the allocation con-
cealment, double blinding, and withdrawals/dropouts
(Clarke and Oxman, 2003; Kjaergard et al., 2001; Moher et
al., 1998; Schulz et al., 1995).
Data abstraction
Two reviewers (J.L. and Y.S.) extracted the data inde-
pendently, and any disagreement was resolved by discus-
sion. The following study characteristics were tabulated
from trials: design, participants and diagnosis, intervention
regimen, and clinical outcomes. Outcome measures to be
extracted included death, number of complications, symp-
toms, quality of life, use of glucocorticoids, findings on chest
radiograph, biochemistry, and adverse events.
Data synthesis
We used the statistical package (RevMan 4.2.3) provided
by The Cochrane Collaboration for data analyses. Dichoto-
mous data were presented as relative risk (RR) and contin-
uous outcomes as weighted mean difference (WMD), both
with 95% confidence interval (CI). We assessed data by both
random effects and fixed effect analyses, but only reported
the fixed effect analysis if the overall conclusion was the
same with both analyses. We assessed heterogeneity by the
I2 statistic and used p  0.10 as a significance limit for het-
erogeneity (Higgins et al., 2003). An exploratory analysis
was performed using data from the nonrandomized studies.
Publication bias was examined by funnel plot, that is, a
graphical display of sample size plotted against effect size,
if data allowed (Egger et al., 1997).
RESULTS
Description of studies
We identified 193 records on SARS from electronic and
manual searches (Fig. 1). By reading titles and abstracts, we
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excluded 131 citations that were clearly duplicates, review
articles, or nonclinical studies. A total of 62 articles pub-
lished in Chinese or English were retrieved for further as-
sessment. Of these, 46 articles were excluded because they
were noncontrolled clinical studies including case reports
and case series. In total, 8 randomized clinical trials (Bian
et al., 2003; Kang et al., 2003; Lei et al., 2003; Li et al.,
2003d; Wang et al., 2003; Zhang, 2003; Zhang et al., 2003;
Zhao et al., 2003) were identified and they reported to al-
locate SARS patients randomly (n  488) to herbal medi-
cine plus conventional drugs or to conventional drugs alone.
The characteristics of 8 randomized trials are summarized
in Table 1. Two of the trials had been published twice (Wang
et al., 2003; Zhang et al., 2003). We also identified 8 non-
randomized controlled studies (Dai et al., 2003; He et al.,
2003; Jiao et al., 2003; Li et al., 2003a, 2003b; Sun et al.,
2003; Zhang et al., 2003) that compared herbal medicine
plus conventional drugs to conventional drugs alone for
SARS patients (n  605) (Table 2). One of the studies had
been published four times in different journals (Li et al.,
2003c).
All eight randomized trials were small, ranging from 40
to 91 participants per trial. All trials included Chinese pa-
tients with SARS. The trial reports did not state whether the
diagnosis was confirmed by laboratory testing. The types,
constituents, dosages, and methods of administration of the
herbal medicines used for treating SARS varied, and most
of the trials used several different herbal medicines during
the disease course (Table 1).
Methodological quality of included studies
Of the eight trials, only two described the method to gen-
erate the allocation sequence (both used random number ta-
bles) (Bian et al., 2003; Wang et al., 2003). No trial pro-
vided information on allocation concealment, double blind-
ing, withdrawals/dropouts, intention-to-treat, or prior sam-
ple size estimation. Accordingly, the included trials had gen-
erally low methodological quality (Bian et al., 2003; Kang
et al., 2003; Lei et al., 2003; Li et al., 2003e; Wang et al.,
2003; Zhang et al., 2003a, 2003b; Zhao et al., 2003). Four
of eight trials failed to provide baseline data for the com-
parability between groups (Lei et al., 2003; Zhang et al.,
2003a, 2003b; Zhao et al., 2003).
The eight nonrandomized studies that were compared in
an exploratory analysis also had poor quality in terms of de-
sign, methodology, and reporting (Table 3) (Dai et al., 2003;
He et al., 2003; Jiao et al., 2003; Li et al., 2003a, 2003b,
2003c; Sun et al., 2003; Zhang et al., 2003). Outcomes are
summarized in Tables 3 and 4.
Mortality
A meta-analysis of five randomized trials (Li et al., 2003e;
Wang et al., 2003; Zhang et al., 2003a, 2003b; Zhao et al.,
2003) showed that a statistically significant difference in
mortality existed between the combined therapy and the con-
ventional drugs in patients with SARS (RR 0.32 [95% CI
0.12 to 0.91]; n  294). The I2 statistic indicated no signif-
icant heterogeneity among the trials. Three trials did not pro-
vide data on death. Pooling data from six non-randomized
controlled studies (Dai et al., 2003; He et al., 2003b, 2003c;
Sun et al., 2003; Zhang et al., 2003) showed a statistically
significant beneficial effect of combined therapy compared
to conventional drugs (0.27 [0.12 to 0.61]; n  486) with
no significant heterogeneity.
Fever and symptom
Three randomized trials (Lei et al., 2003; Li et al., 2003e;
Zhao et al., 2003) showed a significant benefit of the com-
bined therapy versus conventional drugs in shortening the
duration of fever. A pooled result of two trials (Lei et al.,
2003; Li et al., 2003e) showed significant benefit from the
combined therapy versus conventional drugs in shortening
the time to symptom relief. One trial (Bian et al., 2003) eval-
uated quality of life in 40 patients with SARS at the con-
valescent stage, and the scales used included limitation in
activity, difficulty in breathing, and emotion. The results
showed no significant difference in the overall scores of
quality of life comparing combined therapy versus conven-
tional drugs.
Chest radiograph abnormalities
Seven trials reported outcome of lung radiograph (Kang
et al., 2003; Lei et al., 2003; Li et al., 2003e; Wang et al.,
2003; Zhang et al., 2003a, 2003b; Zhao et al., 2003). A meta-
analysis showed significant benefit of the combined therapy
versus conventional drugs in shortening the average time to
resolution of the lung inflammation from three trials (Lei et
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FIG. 1. Flow chart of study selection.
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TABLE 3. COMPARISON OF RANDOMIZED AND NONRANDOMIZED STUDIES ON MORTALITY
Review: Chinese herbal medicine for severe acute respiratory syndrome
Comparison: 01 Herbal medicine plus conventional drugs versus conventional drugs
Outcome: 01 Mortality
Studya Combined therapy Conventional drugs RR (fixed) Weight RR (fixed)
or subcategory n/N n/N 95% CI % 95% CI
Randomized clinical trials
Li et al.a 0/14 0/14 Not estimable
Wang et al.b 1/35 2/30 15.72 0.43 (0.04, 4.50)
Zhang (2003a)a 2/31 6/32 43.11 0.34 (0.08, 1.58)
Zhang et al.c 1/32 4/29 30.64 0.23 (0.03, 1.91)
Zhao et al.a 0/37 1/40 10.53 0.36 (0.02, 8.56)
Subtotal (95% CI) 149 145 100.00 0.32 (0.12, 0.91)
Total events: 4 (combined herapy), 13 (conventional drugs)
Test for heterogeneity: 2  0.17, df  3 (p  0.98), I2  0%
Test for overall effect: Z  2.15 (p  0.03)
Non-randomized controlled studies
Dai et al.a 0/77 3/69 15.74 0.13 (0.01, 2.44)
He et al.a 2/43 2/48 8.06 1.12 (0.16, 7.59)
Li N et al.a 0/35 1/24 7.55 0.23 (0.01, 5.45)
Li XHd,e,f 2/73 9/39 50.06 0.12 (0.03, 0.52)
Sun et al.a 1/80 5/18 13.13 0.45 (0.06, 3.26)
Zhang et al.a 0/22 1/30 5.45 0.45 (0.02, 10.54)
Subtotal (95% CI) 258 228 100.00 0.27 (0.12, 0.61)
Total events: 5 (combined herapy), 21 (conventional drugs)
Test for heterogeneity: 2  3.90, df  5 (p  0.56), I2  0%
Test for overall effect: Z  3.17 (p  0.002)
0.01 0.1 1 10 100
Favors Favors 
herbs drugs
RR, relative risk; CI, confidence interval.
aReference is in References section.
bWang RB, Liu JM, Jiang YY, Wu YZ, Wang XJ, Chi PP, et al. Preliminary study on clinical efficacy of integrative Chinese and
western medicine in treating severe acute respiratory syndrome (SARS). Chin J Integr Trad West Med 2003;23:492–493.
cZhang XM, Feng GL, Ma YM. Clinical recording of infectious atypical pneumonia (SARS) treated by integrated Chinese and west-
ern medicines. China’s Naturopathy. 2003;11:4–6.
dLi XH, Hu JH, Zhang K, Ye J, Gou CY, Li Y, et al. Clinical effective observation on integrated traditional Chinese and western
medicine in treatment of 51 severe SARS patients. Chin J Integr Trad West Med Intens Crit Care 2003d;10:259–261.
eLi XH, Zhang K, Hu JH, Guo XH, Hu ZJ, Yang Y, et al. Clinical observation on effects of treatment of severe acute respiratory
syndrome (SARS) by integrative Chinese and western medicine. Chin J Integr Trad West Med 2003e;23:489–491.
fLi XH, Zhang K, Hu JH, Guo XH, Hu ZJ, Yang Y, et al. Clinical evaluation of integrative Chinese and western medicine in treat-
ing SARS. Chin J Integr Med 2003f;9:181–184.
al., 2003; Li et al., 2003e; Zhang et al., 2003a) and reduc-
ing the number of lung radiographic abnormalities from two
trials (Kang et al., 2003; Zhang et al., 2003b). The remain-
ing trials did not provide adequate lung radiographic data
for analyses because of incomplete reporting.
Glucocorticoids and secondary fungal infections
Five trials (Kang et al., 2003; Li et al., 2003e; Zhang
et al., 2003a, 2003b; Zhao et al., 2003) reported the
dosages of methylprednisolone used in both intervention
groups. The combined result of three trials (Li et al.,
2003e; Zhang et al., 2003a; Zhao et al., 2003) did not show
significant glucocorticoid-reducing effect of the combined
therapy compared to conventional drugs using random ef-
fects model due to significant heterogeneity (I2  99.2%;
p  0.00001). Two trials (Kang et al., 2003; Zhang et al.,
2003b) reported average daily dosage of methylpred-
nisolone, and there was no significant difference between
the treatment groups. A pooled result of two trials (Kang
et al., 2003; Wang et al., 2003) showed significant bene-
fit of the combined therapy versus conventional drugs on
reducing the number of secondary fungal infections in pa-
tients with SARS treated with glucocorticoid (RR 0.35
[0.14 to 0.90]; p  0.03).
No trial provided information on adverse events.
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DISCUSSION
Based on this review and meta-analyses, herbal medicines
given in combination with conventional drugs seem supe-
rior to conventional drugs alone for patients with SARS.
Herbal medicines show benefit on mortality and on short-
ening the duration to temperature normalization, symptom
relief, and resolution of chest radiograph abnormalities, as
well as on reducing the incidence of fungal infections. We
cannot draw conclusions about the safety of using herbal
medicine because no trial provided information on adverse
events.
Before accepting the findings of this review to form a ba-
sis for clinical practice, one must consider the following
weaknesses. First, the randomized trials in this review had
several methodological flaws in terms of generation of the
allocation sequence, allocation concealment, and blinding.
They provided limited descriptions of study design, and
most trials stated only that patients were randomly assigned;
thus the information does not allow a judgment of whether
or not it was conducted properly. We therefore caution that
the differences between the combined treatment and con-
ventional drugs may be associated with the methodologi-
cally less rigorous trials (Clarke and Oxman, 2003; Kjaer-
gard et al., 2001; Moher et al., 1998; Schulz et al., 1995).
The number of trials identified limits us to perform mean-
ingful subgroup or sensitivity analyses to illuminate robust-
ness of the results in the review.
Second, epidemiologic studies on SARS have shown that
age of the patients is strongly associated with mortality
(Donnelly et al., 2003; World Health Organization, 2003b).
None of the randomized trials used age as a stratification
variable during randomization in spite of the fact that all tri-
als were small. Furthermore a number of the trials and non-
randomized studies lack reporting of baseline data of the
groups, including age. Therefore, unbalanced distribution of
the important prognostic variable age between the interven-
tion groups may partly explain the significant findings of
the present systematic review.
Third, Vickers and colleagues (1998) found that some
countries, including China, publish unusually high propor-
tions of positive results, for which publication bias is a pos-
sible explanation. All identified studies for this systematic
review was originating from China. The number of trials
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TABLE 4. SUMMARY FOR OUTCOME VARIABLES OF RANDOMIZED CLINICAL TRIALS
Herbal Conventional
No. of trials medicines drugs Relative risk p
(references)a (events/pts) (events/pts) (95% confidence interval) value
Mortality 5 (Li et al., 2003e; 4/149 13/145 0.32 (0.12 to 0.91) 0.03
Wang et al., 2003;
Zhang et al., 2003a,
2003b; Zhao et al.,
2003)
Incidence of secondary 2 (Kang et al., 2003; 6/780 9/500 0.35 (0.14 to 0.90) 0.03
fungal infection Wang et al., 2003)
Abnormal chest 2 (Kang et al., 2003; 10/740 24/520 0.29 (0.15 to 0.56) 0.0002
radiograph Zhang et al., 2003)
Weighted mean difference
No. of pts. No. of pts. (95% confidence interval)
Duration to fever 3 (Lei et al., 2003; 95 87 0.83 (1.30 to 0.35) 0.0006
clearance (days) Li et al., 2003;
Zhang et al., 2003)
Duration to symptom 2 (Lei et al., 2003; 64 55 1.23 (2.09 to 0.37) 0.005
relief (days) Li et al., 2003e)
Duration to resolution 3 (Lei et al., 2003; 95 80 2.27 (3.16 to 1.39)  0.00001
of chest radiograph Li et al., 2003e;
Zhang et al., 2003a)
Total dosage of 3 (Li et al., 2003e; 60 59 770.45 (1798.47 to 257.58)b 0.14
glucocorticoids (mg) Zhang et al., 2003;
Zhao et al., 2003)
Daily dosage of 2 (Kang et al., 2003; 74 52 54.13 (120.63 to 12.38) 0.11
glucocorticoids (mg) Zhang et al., 2003)
Quality of life (score) 1 (Bian et al., 2003) 20 20 2.20 (4.93 to 0.53) 0.11
aReferences are in References section.
bRandom effects model.
identified in this review is too small for us to explore quan-
titatively the possibility of publication bias. But we note that
some studies, both randomized and nonrandomized, have
been published several times with the same data set.
Fourth, the use of herbal medicines varied both among the
trials as well as during the conduct of the individual trials.
This adds to the complexity of interpreting the present find-
ings. TCM drug treatment, however, consists typically in
complex prescriptions of combination of several components
and uses such flexible administration of interventions so that
they can be adjusted to reflect changes in the patient’s con-
dition or syndrome (Chan, 1995). The combination is based
on the Chinese diagnosis that follows a completely different
rationale than many Western herbal treatments.
Given the low methodological quality of the randomized
trials, the risks of unbalanced distribution of prognostic fac-
tors and the publication bias, the multitude of different herbs
used, and the small size of trials, we find it premature to
conclude that the combination of herbal medicines and con-
ventional drugs has been proven superior to conventional
drugs alone for SARS patients. In spite of the fact that our
exploratory analysis supported the findings from the ran-
domized trials, nonrandomized studies may overestimate
and underestimate intervention effects (Kunz et al., 2003).
Hence, using nonrandomized studies in support of poten-
tially biased clinical trials may be unreliable.
The use of glucocorticoids for patients with SARS re-
mains controversial (Li et al., 2003d; Oba, 2003; Wang,
2003), and to date there is no randomized trial evidence to
support or reject benefit or harm. Adverse effects from large
doses of glucocorticoids are obvious, such as increased risks
of secondary infection (Lionakis and Kontoyiannia, 2003).
In the trials included in this review, we noticed that methyl-
prednisolone was widely used for SARS in China, and the
more severe the patients’ conditions, the larger the dosage
of glucocorticoids was used. However, the trials did not re-
port long-term adverse effects from the use of glucocorti-
coids. Based on our personal contact with doctors who
treated SARS patients in China and on information from the
Internet (Xu, 2003), we have been informed that 20%–40%
of SARS affected health professionals in Beijing had
femoral head necrosis at discharge from the hospital. Early
reports of case series in Guangzhou claimed that Chinese
medicine combined with conventional drugs could reduce
the dosage of corticosteroids (Lin et al., 2003). Our meta-
analyses do not confirm this claim. However, findings from
two trials show a benefit of the combined therapy in reduc-
ing the risk of secondary fungal infections, which may be
related to the use of high doses of steroids. The mechanism
of this benefit is not clear.
We also lack evidence from randomized trials that any of
the conventional drugs, such as ribavirin or interferon
(Loutfy et al., 2003), are effective. We have been unable to
identify trials that compare either herbal medicines or con-
ventional drugs to placebo for SARS patients. We only were
able to identify one case series using herbal medicines alone
for treatment of 16 SARS patients (Tong et al., 2003). In
preparation for new outbreaks, investigators ought to de-
velop international protocols for further well-designed clin-
ical trials, which can be ready when new cases appear.
New treatment options are still needed, especially for an
emerging disease such as SARS. Apart from this review on
herbs, an in vitro study showed that glycyrrhizin (extract
from liquorice root) may inhibit replication of the SARS-
associated virus (Cinatl et al., 2003). Compared to the global
case fatality rate of 11% (916/8422) by August 7, 2003, the
fatality rates for Mainland China, Hong Kong, and Taiwan
are 7% (349/5327), 17% (300/1755), and 27% (180/665),
respectively (World Health Organization, 2003b). We do not
know if these figures represent a potential benefit from the
broad incorporation of herbal medicines into conventional
treatment in Mainland China, or the lower case fatality rates
reflect a cohort of healthier patients or the effect of differ-
ent methods of fatality calculations in different regions
(World Health Organization, 2003a).
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